Guillain-Barré Syndrome Market to reach value of US$ 708.6 Mn by 2025, Says TMR
Akari Therapeutics Plc - American Depositary Shares (AKTX)
US:NASDAQ Investor Relations:
investor.akaritx.com/investor-relations
Company Research
Source: GlobeNewswire
Albany, New York, April 30, 2018 (GLOBE NEWSWIRE) -- The global Guillain–Barré syndrome market was valued at US$ 454.0 Mn in 2016 and is expected to expand at a high CAGR of 5% from 2017 to 2025, to reach value of US$ 708.6 Mn by 2025, according to a new report published by Transparency Market Research (TMR) titled “Guillain–Barré Syndrome Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025.” The report suggests that the growing prevalence of Guillain–Barré syndrome and rising rate of its diagnosis in developing countries is likely to drive the Guillain–Barré syndrome market from 2017 to 2025. North America is projected to dominate the global Guillain–Barré syndrome market during the forecast period, followed by Asia Pacific. The market in the region is primarily driven by factors such as highly structured health care industry and availability of well-defined reimbursement policies for rare diseases from private and public health insurance firm
Show less
Read more
Impact Snapshot
Event Time:
AKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKTX alerts
High impacting Akari Therapeutics Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AKTX
News
- Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 [Yahoo! Finance]Yahoo! Finance
- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024GlobeNewswire
- Akari Therapeutics, Plc (NASDAQ: AKTX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
AKTX
Sec Filings
- 4/11/24 - Form 8-K
- 4/1/24 - Form 8-K
- 3/29/24 - Form 10-K
- AKTX's page on the SEC website